DECEMBER 2022LIFE SCIENCES REVIEW6The European drug discovery market is buoyant and is projected to expand by 8.3 per cent until 2030. France, Germany, and the United Kingdom are the top three European biotech hubs, representing half of all European biotechs (home to the biggest biotech centre). Additionally, the market for small molecule drug delivery in Europe is projected to reach US$ 13,381.71 million by 2027 and increase at a CAGR of 9.0 per cent during that time.Drug discovery has progressed significantly with developing technologies, making the procedure more refined, accurate, and less time-consuming. Utilising cutting-edge technology, such as high throughput techniques, bioinformatics, and combinatorial chemistry, has increased in recent years for better drug candidate documentation. In the upcoming years, it is anticipated that the usage of artificial intelligence systems in disease diagnosis and treatment will rise significantly.This edition of Life Sciences Review highlights the key developments in Europe's drug discovery and development space. It features a combination of thought leadership articles from Itedale Namro Redwan, CSO, CELLINK and Carlos Pedraza, PhD., Director of CNS Biology, Alkermes, with real-life stories on fostering robust partnerships and exclusive insights from CIOs and CXOs. This edition also brings you the stories of some of the most successful Small Molecules Drug Discovery and Development Solutions Providers in Europe - 2022, like ALPX and SPILLOproject. ALPX offers fully automated and remote-controlled protein-to-structure pipelines for protein crystallography and fragment and compound screening. The ALPX high-throughput services enable researchers to solve crystal structures faster, thus accelerating research in a range of fields from pharma to biotech. SPILLOproject provides a spectrum of specific services to optimise various drug discovery and development phases. It can identify the targets responsible for the therapeutic effects of a small molecule, which helps design targeted modifications to improve its affinity (Rational Drug Design). With a plethora of solution providers in the market, this edition aims to provide you with assistance in choosing suitable small molecules drug discovery and development solution providers according to your requirements. We present to you the Top 10 Small Molecules Drug Discovery and Development Solutions Providers in Europe - 2022 and Top 10 Drug Discovery and Development Solutions Providers in Europe 2022.Let us know your thoughts.EDITORIALInnovative Technologies Driving the Next Life Science Revolution Copyright © 2022 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasGilbert HooverAncel CastelinoDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsDecember - 12 - 2022, Vol 03, Issue - 15 (ISSN 2831-8323) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com VisualizersRonald DonovanVictor Cruz Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com
< Page 5 | Page 7 >
< Page 5 | Page 7 >